Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04865887 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 4 months later Jul 2026 → Dec 2027
See other at-risk trials from Georgetown University

Record History

  1. Primary completion pushed from Jul 2026 to Dec 2027 Completion pushed from Jul 2026 to Jul 2028v15 Show 1 more changeShow less
    • Completion pushed from Jul 2026 to Jul 2028
  2. Primary and study completion dates: Jul 2025 to Jul 2026v14
  3. Site contacts updated at 1 of 4 sitesv13
  4. Site details revised at 2 of 4 sitesv12
  5. Primary and study completion dates: Jul 2024 to Jul 2025 Site details revised at 1 of 4 sitesv11 Show 1 more changeShow less
    • Site details revised at 1 of 4 sites
Show 9 earlier versionsHide 9 earlier versions
  1. Study sites: 3 to 4v10
  2. Primary and study completion dates: Jul 2023 to Jul 2024v9
  3. Start date changed from estimate of Nov 2022 to Oct 7, 2022 Site contacts updated at 1 of 3 sitesv8 Show 1 more changeShow less
    • Site contacts updated at 1 of 3 sites
  4. Start date: Aug 2022 to Nov 2022v7
  5. Start date: Jun 2022 to Aug 2022 Site details revised at 1 of 3 sitesv6 Show 1 more changeShow less
    • Site details revised at 1 of 3 sites
  6. Start date: Mar 2022 to Jun 2022v5
  7. Trial status: Not Yet Recruiting to Recruiting Start date: Dec 2021 to Mar 2022 · Study sites: 2 to 3v4 Show 2 more changesShow less
    • Start date: Dec 2021 to Mar 2022
    • Study sites: 2 to 3
  8. Start date: Oct 2021 to Dec 2021v3
  9. Start date: Jul 2021 to Oct 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.
Trial Details
NCT Number NCT04865887
Lead Sponsor Georgetown University
Collaborators: Merck Sharp & Dohme LLC
Conditions Cervical Cancer, Metastatic Cervical Cancer
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov